An innovative phase II trial to establish proof of efficacy and optimal dose of a new inhaled epithelial sodium channel inhibitor BI 1265162 in adults and adolescents with cystic fibrosis: BALANCE-CFTM 1

Christopher H. Goss, Raksha Jain, Wolfgang Seibold, Anne-Caroline Picard, Ming-Chi Hsu, Abhya Gupta, Isabelle Fajac

Source: ERJ Open Res, 6 (4) 00395-2020; 10.1183/23120541.00395-2020
Journal Issue: October
Disease area: Airway diseases, Paediatric lung diseases

Congress or journal article abstractFull text journal articlePDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Christopher H. Goss, Raksha Jain, Wolfgang Seibold, Anne-Caroline Picard, Ming-Chi Hsu, Abhya Gupta, Isabelle Fajac. An innovative phase II trial to establish proof of efficacy and optimal dose of a new inhaled epithelial sodium channel inhibitor BI 1265162 in adults and adolescents with cystic fibrosis: BALANCE-CFTM 1. ERJ Open Res, 6 (4) 00395-2020; 10.1183/23120541.00395-2020

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: